Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients

• Published in: Scientific reports Vol. 7; no. 1; pp. 17480 - 9
• Main Authors: Yu, Wenxi, Liu, Zimei, Tang, Lina, Lin, Feng, Yao, Yang, Shen, Zan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12.12.2017; Nature Publishing Group
• Subjects: 692/308/409; 692/4028/67/1344; Bone cancer; Chemotherapy; Humanities and Social Sciences; Lung cancer; Metastases; Metastasis; multidisciplinary; Osteosarcoma; Radiosurgery; Sarcoma; Science; Science (multidisciplinary); Surgery; Survival; Toxicity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-14521-7

Osteosarcoma pulmonary metastases are typically treated with resection and/or chemotherapy. We hypothesize that stereotactic radiosurgery (SRS) can be an alternative to surgery that can achieve high rates of local control with limited toxicity. From January 2005 to December 2013, 73 patients who developed pulmonary metastasis during period of adjuvant chemotherapy or follow-up were analyzed. 33 patients were treated by stereotactic radiosurgery using the body gamma-knife system. A total dose of 50 Gy was delivered at 5 Gy/fraction to the 50% isodose line covering the planning target volume, whereas a total dose of 70 Gy was delivered at 7 Gy/fraction to the gross target volume. The other 40 patients were treated by surgical resection. Four-year progression-free survival rate, four-year survival rate, median time of PRPFS (post-relapse progress-free survival) and PROS (post-relapse overall survival) in SRS group were parallel to that in surgical group. Patients tolerated gamma knife radiosurgery well. Our study demonstrates that SRS is well-tolerated with excellent local control and less complications. SRS should be considered as a potential option in patients with pulmonary metastases from osteosarcoma, especially in those who are medically inoperable, refuse surgery.